35 results about "Terbutaline" patented technology

The invention relates to the technical field of preparation and application of chiral high-performance liquid chromatography column materials, and discloses preparation and application of beta-CD-D2 high-performance liquid chromatography chiral column material. A high-performance liquid chromatography chiral column is prepared from beta-CD-D2 and is used for splitting chiral medicine enantiomers. The preparation and the application of the beta-CD-D2 high-performance liquid chromatography chiral column material comprise the following steps: 1, constructing a chiral environment by using beta-CD-D2, bonding the chiral environment with high-performance liquid chromatography silica beads into a fixed phase filler, then preparing the fixed phase filler into a chiral column, and applying the chiral column into high-performance liquid chromatography; 2, finding out an optional formula and an optional condition by using a proper characterization means, and optimizing the method and the condition; 3, establishing a preparation method of a salmeterol single enantiomer by using the prepared beta-CD-D2 chiral column, and splitting a chiral compound by using a cyclodextrins derivative for the first time; and 4, splitting drugs by using the prepared beta-CD-D2 chiral column, and establishing a method for splitting and qualitatively and quantitatively analyzing seven chiral drugs including salmeterol, terbutaline, procaterol, cetirizine, lamivudine, cefuroxime and ceftriaxone.

This invention disclosed new use of R-terbutaline and other R-enantiomer [beta]2-agonists as immune-modulators for treatment of bronchia-lung inflammatory symptoms or inflammatory fibrosis remolding. This invention also disclosed new use of R-terbutaline and R-[beta]2-agonists for reduced adverse effects related to racemic or S-enantiomer [beta]2-agonists including airway hyper responsiveness and airway fibrosis.

The invention relates to the field of biotechnology, and discloses an anti-β-receptor agonist cluster-specific monoclonal antibody hybridoma cell line and the monoclonal antibody secreted therefrom. The hybridoma cell line of the present invention is prepared from salbutamol artificial antigen, and the monoclonal antibody secreted by it can simultaneously recognize salbutamol, clenbuterol hydrochloride, terbutaline, bromobuterol and sibuterol and other β-receptor agonists, Has cluster specificity; the immunoaffinity chromatography gel prepared from this is mixed with other β‑receptor agonists, such as ractopamine, as a purification reagent for machine test pretreatment and HPLC‑FLD, LC‑MS / The combination of MS detection technology can efficiently detect various clenbuterol components in pork, pig liver and pig urine samples, with high accuracy and sensitivity.

The invention discloses an electrochemical immunosensor capable of detecting various beta-adrenergic receptor stimulants (short for beta-stimulants). The sensor comprises a base electrode, a graphene / chitosan complex membrane and multi-determinant antigens of beta-stimulants, wherein the graphenee / chitosan complex membrane is modified on the surface of the base electrode, and the multi-determinant antigens of the beta-stimulants are fixed on the surface of the graphene / chitosan complex membrane. The multi-determinant antigens fixed on the surface of the sensor are salbutamol-ractopamine-BSA or salbutamol-ractopamine-OVA. The invention also provides an electrochemical immunodetection method for various beta-stimulant residues. The electrochemical immunosensor can be used for detecting six beta-stimulants including clenbuterol, salbutamol, ractopamine, terbutaline, mabuterol and tulobutezol through carrying out cross immune reaction on the beta-stimulants based on wide-spectrum specific antibodies of the beta-stimulants by taking K3[Fe(CN)6] as a probe.